慢性乙型病毒性肝炎患者经恩替卡韦治疗后发生低病毒血症的影响因素  

Influencing factors of low-level viremia in patients with chronic hepatitis B treated with Entecavir

作　　者：孔宁 KONG Ning(Infection Department of Henan Hongli Hospital,Xinxiang 453400 Henan,China)

机构地区：[1]河南宏力医院感染科,河南新乡453400

出　　处：《中国民康医学》2025年第4期16-19,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:分析慢性乙型病毒性肝炎(CHB)患者经恩替卡韦治疗后发生低病毒血症(LLV)的影响因素。方法:回顾性分析2020年1月至2023年1月该院收治的76例接受恩替卡韦治疗的CHB患者的临床资料,统计治疗后LLV发生情况,依据患者病毒学应答情况[乙型肝炎病毒脱氧核糖核酸(HBV-DNA)载量持续或间歇检测≤2000 U/mL,为LLV;HBV-DNA载量持续性<20 U/mL,为持续病毒学应答(SVR)]将其分为LLV组和SVR组,采用Logistic回归分析慢性乙型病毒性肝炎患者经恩替卡韦治疗后发生LLV的影响因素。结果:LLV组依从性不佳、乙型肝炎e抗原(HBeAg)阳性、乙型肝炎病毒表面抗原(HBsAg)阳性、HBV-DNA定量>200 U/mL等占比均高于SVR组,差异有统计学意义(P<0.05);经Logistic回归分析结果显示,依从性不佳、HBeAg阳性、HBsAg阳性、HBV-DNA定量>200 U/mL等均为影响CHB患者经恩替卡韦治疗后发生LLV的危险因素(OR>1,P<0.05)。结论:依从性不佳、HBeAg阳性、HBsAg阳性、HBV-DNA定量>200 U/mL等均为影响CHB患者经恩替卡韦治疗后发生LLV的危险因素。Objective:To analyze influencing factors of low-level viremia(LLV)in patients with chronic hepatitis B(CHB)treated with Entecavir.Methods:The clinical data of 76 CHB patients treated with Entecavir in this hospital from January 2020 to January 2023 were retrospectively analyzed.The occurrence of LLV after the treatment was statistically analyzed.According to the patients’virological response[hepatitis B virus deoxyribonucleic acid(HBV-DNA)load persistence or intermittent detection≤2000 U/mL,LLV;HBV-DNA load persistence<20 U/mL,sustained virological response(SVR)],they were divided into LLV group and SVR group.Logistic regression was used to analyze the influencing factors of LLV in the patients with chronic hepatitis B treated with Entecavir.Results:The proportions of the patients with poor compliance,hepatitis B e antigen(HBeAg)positive,hepatitis B virus surface antigen(HBsAg)positive,and HBV-DNA quantification>200 U/mL in the LLV group were higher than those in the SVR group,and the differences were statistically significant(P<0.05).Logistic regression analysis showed that poor compliance,HBeAg positive,HBsAg positive,and HBV-DNA quantitative>200 U/mL were all risk factors for LLV in the CHB patients after Entecavir treatment(OR>1,P<0.05).Conclusions:Poor compliance,HBeAg positive,HBsAg positive,and HBV-DNA quantitative>200 U/mL are the risk factors for LLV in the CHB patients treated with Entecavir.

关 键 词：恩替卡韦 慢性乙型病毒性肝炎 低病毒血症 影响因素 

分 类 号：R512.6[医药卫生—内科学]